A number of firms have modified their ratings and price targets on shares of NanoString Technologies (NASDAQ: NSTG) recently:

  • 9/15/2018 – NanoString Technologies was downgraded by analysts at BidaskClub from a “strong-buy” rating to a “buy” rating.
  • 9/13/2018 – NanoString Technologies had its price target raised by analysts at JPMorgan Chase & Co. to $20.00. They now have an “overweight” rating on the stock.
  • 9/11/2018 – NanoString Technologies had its price target raised by analysts at Robert W. Baird from $15.00 to $18.00. They now have an “outperform” rating on the stock.
  • 8/30/2018 – NanoString Technologies was upgraded by analysts at ValuEngine from a “hold” rating to a “buy” rating.
  • 8/11/2018 – NanoString Technologies was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington. “
  • 8/7/2018 – NanoString Technologies was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $14.00 price target on the stock. According to Zacks, “NanoString Technologies, Inc. is engaged in the development, manufacture and sale of life science tools. It provides nCounter Analysis System which supports research and development of clinical applications from basic discovery to the development of future molecular diagnostic tests on a single platform. The company also offers nSolver Analysis software, gene expression panels, miRNA expression assay kits, cancer copy number variation panels, nCounter leukemia fusion gene expression assay kits and human karyotype panels, custom CodeSets and master kits that are ancillary reagents, cartridges, tips and reagent plates to setup and process samples in its instruments. It markets its systems and related consumables to researchers in academic, government and biopharmaceutical laboratories primarily in North America, Europe, the Middle East and the Asia Pacific. NanoString Technologies, Inc. is headquartered in Seattle, Washington. “
  • 8/3/2018 – NanoString Technologies was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.

NSTG traded down $0.11 on Tuesday, hitting $16.88. The company had a trading volume of 1,514 shares, compared to its average volume of 243,632. NanoString Technologies Inc has a 1-year low of $5.87 and a 1-year high of $18.86. The company has a debt-to-equity ratio of 5.77, a quick ratio of 2.01 and a current ratio of 2.49. The firm has a market cap of $510.86 million, a P/E ratio of -9.17 and a beta of 0.63.

NanoString Technologies (NASDAQ:NSTG) last posted its earnings results on Tuesday, August 7th. The biotechnology company reported ($0.80) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.71) by ($0.09). NanoString Technologies had a negative return on equity of 201.90% and a negative net margin of 54.34%. The company had revenue of $25.00 million during the quarter, compared to analyst estimates of $25.10 million. analysts anticipate that NanoString Technologies Inc will post -2.61 earnings per share for the current fiscal year.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Metropolitan Life Insurance Co. NY acquired a new position in shares of NanoString Technologies during the second quarter worth approximately $108,000. MetLife Investment Advisors LLC acquired a new position in shares of NanoString Technologies during the second quarter worth approximately $155,000. Engineers Gate Manager LP acquired a new position in shares of NanoString Technologies during the second quarter worth approximately $261,000. GSA Capital Partners LLP acquired a new position in shares of NanoString Technologies during the second quarter worth approximately $271,000. Finally, Acadian Asset Management LLC acquired a new position in shares of NanoString Technologies during the second quarter worth approximately $325,000. Hedge funds and other institutional investors own 73.34% of the company’s stock.

NanoString Technologies, Inc provides life science tools for translational research and molecular diagnostic products worldwide. The company offers nCounter Analysis System, an automated, multi-application, digital detection, and counting system. It provides nCounter MAX and FLEX systems that include Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files.

Featured Article: Discover Your Risk Tolerance

Receive News & Ratings for NanoString Technologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NanoString Technologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.